Headache and Migraine

As part of NeurologyLive®'s Year in Review, take a look at our top news articles in headache and migraine in 2024.

As part of NeurologyLive®'s Year in Review, we've compiled the top coverage stories from 2024 across a variety of different neurological conferences the team either attended or covered virtually.

As part of NeurologyLive®'s Year in Review, we've compiled the most-read feature-length stories that appeared on the website in 2024.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on CGRP medications to treat migraine.

Specialized teams at the AHN Headache Center, in Pittsburgh, Pennsylvania, offer crucial diagnoses and novel therapies for patients with migraine.

Perspective from neurologists on the current and future applications for artificial intelligence across a bevy of neurologic conditions.

Catch up on any of the neurology news headlines you may have missed over the course of November 2024, compiled all into one place by the NeurologyLive® team.

Early data from the pilot RELIEV-CM trial showed significant reductions in headache and migraine days, with 56% of patients showing a 50% reduction in symptoms at 4 weeks, and 100% at 12 weeks.

The findings suggest that future phase 3 trials should explore the duration of pain relief and headache recurrence, with the goal of developing structured treatment guidelines for PTH.

Nerivio, a nondrug option for acute migraine attacks and prevention of migraine with or without aura, has been FDA-approved for several years in adolescents aged 12 and older as well as adults.

Catch up on any of the neurology news headlines you may have missed over the course of October 2024, compiled all into one place by the NeurologyLive® team.

STS101 showed promising results in previous trials, with significant pain relief and minimal adverse events reported, reinforcing its potential as a viable treatment for patients with migraine.

In the study, both migraine and gestational diabetes mellitus independently increase the risk of premature major cardiovascular and cerebrovascular events, with the highest risk observed among those with both conditions.

Over months 4 through 6, 69.1% of participants on erenumab 140 mg, and 60.3% of the erenumab 70 mg group achieved MOH remission compared with 52.6% of those on placebo

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on medication overuse headaches.

Catch up on any of the neurology news headlines you may have missed over the course of September 2024, compiled all into one place by the NeurologyLive® team.

Michelle Bravo, MD, an assistant professor of clinical neurology at the University of Miami, provided commentary on a rare case report of a subdural hematoma linked to spontaneous intracranial hypotension caused by a refractory CSF leak.

Over half of the patients (56.7%) discontinued at least one class of acute migraine medication within 12 months post-erenumab initiation.

The phase 2 study, expected to include 575 patients with acute migraine, will use percentage of participants with freedom from pain and freedom from the most bothersome symptom as the coprimary end points.

Transition to college life poses unique challenges for students living with migraine, and a comprehensive checklist helps ensure they are prepared for this critical phase.

Nina Riggins, MD, PhD, FAAN, FAHS, UCNS Diplomate, highlighted the essential role of advocacy in advancing neurological care, particularly in improving the transition process for pediatric patients with migraine to adult care.

Stewart Tepper, MD, Vice President at the New England Institute for Neurology and Headache in Stamford, Connecticut, provided commentary on a wide-scale analysis of nearly 5000 patients testing the effects of rimegepant.

Neurology News Network. for the week ending September 14, 2024. [WATCH TIME: 4 minutes]

Treatment with Lu AG09222 as a migraine preventive was safe, with common adverse events that included COVID-19, nasopharyngitis, and fatigue.

Across 4 trials with over 4800 patients, rimegepant demonstrated superior pain and symptom relief 2 hours post-dose, with fewer requiring rescue medication.

CT-132, a digital therapy, targets brain hypersensitivity and provided non-pharmacological treatment, showing promise for integration into migraine management.

Neurology News Network. for the week ending September 7, 2024. [WATCH TIME: 4 minutes]

AXS-07 has been supported by data from 2 major phase 3 trials in which treatment with the agent led to significant reliefs in pain freedom, the most bothersome symptoms, and acute medication use.

The system is composed of the Neuroblade, a single-use multifunctional neuroendoscope; the Neuropad, a reusable medical-grade tablet; and Clearpath, a disposable transparent access sheath.

In a 3-month trial at two primary care sites, neurology referrals decreased by 77%, and brain MRI scans dropped by 35%.